These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 15980026)

  • 41. How long should we treat community-acquired pneumonia?
    Scalera NM; File TM
    Curr Opin Infect Dis; 2007 Apr; 20(2):177-81. PubMed ID: 17496577
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The management of patients with community-acquired pneumonia beyond antibiotic therapy.
    Aliberti S; Blasi F
    Eur J Intern Med; 2012 Jul; 23(5):389-90. PubMed ID: 22726365
    [No Abstract]   [Full Text] [Related]  

  • 43. Community-acquired pneumonia in children.
    Dennehy PH
    Med Health R I; 2010 Jul; 93(7):211-5. PubMed ID: 20704068
    [No Abstract]   [Full Text] [Related]  

  • 44. Monotherapy or combination therapy for hospitalized patients with community-acquired pneumonia: not yet the end of the story?
    Laterre PF
    Clin Infect Dis; 2008 May; 46(10):1510-2. PubMed ID: 18419483
    [No Abstract]   [Full Text] [Related]  

  • 45. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity.
    Singh A
    Clin Infect Dis; 2007 Jul; 45(1):133; author reply 134-5. PubMed ID: 17554716
    [No Abstract]   [Full Text] [Related]  

  • 46. [Clinical efficacy of probiotics in complex treatment of called-up servicemen with community-acquired pneumonia].
    Rakov AL; Grinevich VB; Kriukov AE; Bogdanov IV; Rysev AV; Zakharchenko MM; Dobrenko VA; Gubonina IV
    Voen Med Zh; 2006 Apr; 327(4):15-22. PubMed ID: 16784101
    [No Abstract]   [Full Text] [Related]  

  • 47. Antibiotics in childhood pneumonia.
    Hale KA; Isaacs D
    Paediatr Respir Rev; 2006 Jun; 7(2):145-51. PubMed ID: 16765302
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
    Echols RM; Tillotson GS; Song JX; Tosiello RL
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and microbiological end points in the treatment of pneumonia.
    Musher DM
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S207-9. PubMed ID: 18986291
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Mixed bacterial pneumonia].
    García Rey C; Bouza Santiago E
    Med Clin (Barc); 1998 Feb; 110 Suppl 1():36-9. PubMed ID: 9717159
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
    Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
    Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibiotic treatment of community acquired pneumonia varies widely across Germany.
    Kohlhammer Y; Raspe H; Marre R; Suttorp N; Welte T; Schäfer T;
    J Infect; 2007 May; 54(5):446-53. PubMed ID: 17007933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapy for severe community-acquired pneumonia.
    Berk SL
    Clin Infect Dis; 1997 Jul; 25(1):168-9. PubMed ID: 9243063
    [No Abstract]   [Full Text] [Related]  

  • 54. Community-acquired pneumonia.
    Niederman MS
    Isr Med Assoc J; 2003 Feb; 5(2):133-8. PubMed ID: 12674669
    [No Abstract]   [Full Text] [Related]  

  • 55. Doxycycline for nursing home acquired pneumonia (NHAP).
    Cunha BA
    Scand J Infect Dis; 2009; 41(1):77-8, author reply 76. PubMed ID: 18821134
    [No Abstract]   [Full Text] [Related]  

  • 56. Overview of recent studies of community-acquired pneumonia.
    Higgins K; Singer M; Valappil T; Nambiar S; Lin D; Cox E
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S150-6. PubMed ID: 18986282
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.
    Arguedas A; Cespedes J; Botet FA; Blumer J; Yogev R; Gesser R; Wang J; West J; Snyder T; Wimmer W;
    Int J Antimicrob Agents; 2009 Feb; 33(2):163-7. PubMed ID: 18945594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is it possible to blind a trial for community-acquired pneumonia?
    Boucher HW
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S210-5. PubMed ID: 18986292
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Important factors to consider for patients with community-acquired pneumonia.
    De Maria A; Rana E; Canonica GW
    Clin Infect Dis; 2005 May; 40(9):1374-5; author reply 1375-6. PubMed ID: 15825045
    [No Abstract]   [Full Text] [Related]  

  • 60. Optimizing therapy for community-acquired pneumonia with the goal of rapid resolution of illness.
    File TM; Tan JS
    Clin Infect Dis; 2005 Dec; 41(12):1706-8. PubMed ID: 16288391
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.